A Model to Define Probable Cause
We present a model to discern probable cause out of clinical data. We seek collaboration opportunities with interested health insurers ...
Why We Love Committees
In healthcare, we have a committee for everything. It is how we meet and how we decide. But it also ...
When Law Targets Physicians
When charges are hurled against a physician, all of medicine feels the effects. It cultivates a culture of fear that ...
Prescriptions Cause Inflation?
Many point to rising drug costs as one cause of inflation. But drug costs do not affect consumer pricing, as ...
Confronting COVID Senioritis
COVID fatigue is undeniable and most long to just move on. Instead, we should find a balance between the benefits ...
It’s the Virosphere, Stupid
Recently, we have seen many viruses behave abnormally. It is time to study the virosphere and understand viral behavior in ...
Healthcare Expansionism
The pandemic revealed how social policies affect individual health. But not all things social are directly healthcare related.
The Court of FDA
The FDA makes inconsistent policy decisions with little regard to data. It feigns incompetence to cover for its conflicting incentives.
Can a Physician be a Patriot?
While celebrating the Fourth of July and all that it represents, we pondered whether physicians should do more to protect ...
Vaping: A Tale of Two Crises
Once again, vaping is at the mercy of regulators. The FDA should first understand the origins of the vaping crisis ...
Standardize Medicine by Law
Legal encroachment into medicine creates an artificial conformity. It has led to landmark legal settlements, but poor quality of care.
Gun Rights vs. Gun Outcomes
We often make false equivalencies when debating gun policy. But one thing is clear: there is an inverse relationship between ...
Glucagon-Like Peptide–Based Therapies and Longevity: Clinical Implications from Emerging Evidence
Glucagon-like peptide–based therapies are increasingly used for weight management and glycemic control, but their potential impact on long-term survival remains uncertain. The clinical question addressed in this report is whether treatment with glucagon-like peptide receptor agonists is associated with reductions in all-cause mortality and age-related morbidity beyond their established metabolic effects. This question matters because these agents are now prescribed across broad patient populations, including individuals without diabetes, and long-term exposure may influence cardiovascular, oncologic, and neurodegenerative outcomes. Understanding whether...
Read more